Target Modification and Efflux Mechanisms

Two recurring resistance strategies do not destroy the antibiotic but defeat it inside the cell: altering or protecting the molecule the drug acts on so it no longer binds, and actively pumping the drug back out before it can act. Target modification and efflux together account for resistance to many antibiotic classes and frequently underlie multidrug resistance.

Definition

Target modification is any change that lowers a drug's affinity for its binding site — including mutation, chemical modification such as methylation, protection by a dedicated protein, or replacement of the target by a resistant variant — while efflux is the active transport of the drug out of the cell by membrane pumps; both reduce the effective drug concentration at its site of action.

Scope

This topic covers resistance achieved by changing the drug's target — through mutation, enzymatic modification, target protection, or target replacement — and by active efflux through membrane transporter systems, together with reduced uptake. Enzymatic inactivation of the drug itself is treated in a companion topic. The treatment is mechanistic and microbiological rather than clinical.

Core questions

• How does altering or protecting a drug target confer resistance without destroying the drug?
• What molecular forms can target modification take?
• How do efflux pumps reduce intracellular drug concentration?
• Why do efflux systems often produce resistance to several drug classes simultaneously?

Key concepts

• Target-site mutation
• Target enzymatic modification (e.g., methylation)
• Target protection proteins
• Target replacement and bypass
• Efflux pumps
• Multidrug efflux systems
• Reduced permeability

Mechanisms

Target-based resistance works by lowering the drug's affinity for its site of action. This can occur through mutation of the gene encoding the target, through enzymatic modification of the target such as methylation of ribosomal RNA, through a target-protection protein that binds the target and displaces or shields it from the drug, or through acquisition of an alternative, drug-insensitive version of the target that bypasses the susceptible one. Efflux works differently: membrane transport proteins actively export the antibiotic from the cytoplasm or periplasm, keeping its intracellular concentration below an inhibitory level. Some efflux pumps are narrow in specificity, but broad-substrate multidrug pumps can expel several unrelated drug classes, and efflux often acts together with reduced outer-membrane permeability to limit drug accumulation (Blair et al., 2015; Munita & Arias, 2016; Alekshun & Levy, 2007).

Clinical relevance

Target modification and efflux explain resistance phenotypes that are not reversed by beta-lactamase inhibitors and that often span multiple drug classes, which is reference knowledge for interpreting resistance patterns and cross-resistance. The entry describes these molecular mechanisms and does not provide dosing or treatment recommendations.

Epidemiology

Efflux systems and modifiable targets are widespread across bacterial species, and both intrinsic and acquired forms contribute to resistance globally. Broad-specificity efflux and target-protection genes are found across environmental and clinical isolates, contributing to the recurring, cross-species appearance of multidrug-resistant phenotypes (Davies & Davies, 2010; Blair et al., 2015).

Evidence & guidelines

The mechanistic descriptions here are consolidated from widely cited reviews of molecular resistance (Blair et al., 2015; Munita & Arias, 2016; Alekshun & Levy, 2007). The entry is educational and issues no clinical guidelines.

History

Active efflux as a resistance mechanism was established when tetracycline resistance was traced to an energy-dependent export protein, and subsequent work identified broad-substrate multidrug efflux systems. In parallel, ribosomal and other target modifications, and target-protection proteins, were characterized as distinct routes to resistance, consolidating target alteration and efflux as core categories alongside enzymatic inactivation (Alekshun & Levy, 2007; Blair et al., 2015).

Key figures

• Laura J. V. Piddock
• Stuart B. Levy
• Cesar A. Arias
• Julian Davies

Seminal works

• blair-2015
• alekshun-levy-2007
• munita-arias-2016

Frequently asked questions

How does target modification cause resistance if the drug is still present?

By changing the molecule the drug must bind — through mutation, chemical modification, protection, or replacement — so the drug's affinity drops and it can no longer inhibit its target effectively.

Why do efflux pumps often cause resistance to many drugs at once?

Some efflux pumps have broad substrate specificity and can export several structurally unrelated antibiotics, so a single pump system can reduce intracellular levels of multiple drug classes.